Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism

Our objective was to evaluate the effect of itraconazole, a P‐glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of fexofenadine, a P‐glycoprotein substrate, in relation to the multidrug resistance 1 gene (MDR1) G2677T/C3435T haplotype.

[1]  P. Neuvonen,et al.  Itraconazole increases serum digoxin concentration. , 1996, Pharmacology & toxicology.

[2]  B. Diquet,et al.  Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans , 2004, Fundamental & clinical pharmacology.

[3]  H. Lennernäs,et al.  The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. , 2003, British journal of clinical pharmacology.

[4]  M. Horsmanheimo,et al.  Modulation of the immediate allergic wheal reaction in the skin by drugs inhibiting the effects of leukotriene C4 and prostaglandin D2 , 2001, European Journal of Clinical Pharmacology.

[5]  Rakesh Patel,et al.  Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. , 2004, Journal of chromatography. A.

[6]  Cuiping Chen,et al.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[7]  T. Tsuruo,et al.  P-Glycoprotein-Mediated Transport of Itraconazole across the Blood-Brain Barrier , 1998, Antimicrobial Agents and Chemotherapy.

[8]  J. Beijnen,et al.  The pharmacological role of P-glycoprotein in the intestinal epithelium. , 1998, Pharmacological research.

[9]  H. Lennernäs,et al.  Multiple transport mechanisms involved in the intestinal absorption and first‐pass extraction of fexofenadine , 2003, Clinical pharmacology and therapeutics.

[10]  W. Charman,et al.  The Mucosa of the Small Intestine , 2002, Clinical pharmacokinetics.

[11]  D. Oh,et al.  A variant 2677A allele of the MDR1 gene affects fexofenadine disposition , 2004, Clinical pharmacology and therapeutics.

[12]  S. Gollapudi,et al.  Reversal of daunorubicin resistance in P388/ADR cells by itraconazole. , 1991, The Journal of clinical investigation.

[13]  B. Haehner‐Daniels,et al.  The effect of rifampin administration on the disposition of fexofenadine , 2001, Clinical pharmacology and therapeutics.

[14]  J. Kigawa,et al.  Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.

[15]  C. Wandel,et al.  Increased drug delivery to the brain by P‐glycoprotein inhibition , 2000, Clinical pharmacology and therapeutics.

[16]  G R Wilkinson,et al.  OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[17]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[18]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[19]  P. Neuvonen,et al.  Itraconazole increases plasma concentrations of quinidine , 1997, Clinical pharmacology and therapeutics.

[20]  S. Tufik,et al.  Flunitrazepam-induced changes in neurophysiological, behavioural, and subjective measures used to assess sedation , 2003, Progress in Neuro-psychopharmacology and Biological Psychiatry.

[21]  R. Ho,et al.  (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function , 2004 .

[22]  I Hindmarch,et al.  An evaluation of the effects of high‐dose fexofenadine on the central nervous system: a double‐blind, placebo‐controlled study in healthy volunteers , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  W. L. Nelson,et al.  ROLE OF ITRACONAZOLE METABOLITES IN CYP3A4 INHIBITION , 2004, Drug Metabolism and Disposition.

[24]  R. Kim.  Drugs as P-glycoprotein substrates, inhibitors, and inducers , 2002, Drug metabolism reviews.

[25]  I. Hindmarch,et al.  The effects of acute doses of fexofenadine, promethazine, and placebo on cognitive and psychomotor function in healthy Japanese volunteers. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[26]  J. Coutant,et al.  Determination of terfenadine and terfenadine acid metabolite in plasma using solid-phase extraction and high-performance liquid chromatography with fluorescence detection. , 1991, Journal of chromatography.

[27]  J. Zhi,et al.  The pharmacokinetic‐pharmacodynamic (Digit Symbol Substitution Test) relationship of flumazenil in a midazolam steady‐state model in healthy volunteers , 1994, Clinical pharmacology and therapeutics.

[28]  E. Wang,et al.  Interaction of Common Azole Antifungals with P Glycoprotein , 2002, Antimicrobial Agents and Chemotherapy.

[29]  P. Neuvonen,et al.  Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol , 2003, Clinical pharmacology and therapeutics.

[30]  S. Weir,et al.  Pharmacokinetics, pharmacodynamics, and tolerance of single‐ and multiple‐dose fexofenadine hydrochloride in healthy male volunteers , 1998, Clinical pharmacology and therapeutics.

[31]  D. Greenblatt,et al.  Effects of the Antifungal Agents on Oxidative Drug Metabolism , 2000, Clinical pharmacokinetics.

[32]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Fromm.  The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. , 2002, Advanced drug delivery reviews.

[34]  Jan Stankiewicz,et al.  Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. , 2003, Pharmacogenetics.

[35]  U. Brinkmann,et al.  Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.